Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review
Frédéric Fiteni1,2,4*, Amélie Anota1,2,3, Virginie Westeel5 and Franck Bonnetain1,2,3,6

Abstract
Background: Health-related quality of life (HRQoL) is recognized as a component endpoint for cancer therapy approvals. The aim of this review was to evaluate the methodology of HRQoL analysis and reporting in phase III clinical trials of first-line chemotherapy in advanced non-small cell lung cancers (NSCLC).
Methods: A search in MEDLINE databases identified phase III clinical trials in first-line chemotherapy for advanced NSCLC, published between January 2008 to December 2014. Two authors independently extracted information using predefined data abstraction forms.
Results: A total of 55 phase III advanced NSCLC trials were identified. HRQoL was declared as an endpoint in 27 studies (49 %). Among these 27 studies, The EORTC questionnaire Quality of Life Questionnaire C30 was used in 13 (48 %) of the studies and The Functional Assessment of Cancer Therapy-General was used in 12 (44 %) trials. The targeted dimensions of HRQoL, the minimal clinically important difference and the statistical approaches for dealing with missing data were clearly specified in 13 (48.1 %), 9 (33.3 %) and 5 (18.5 %) studies, respectively. The most frequent statistical methods for HRQoL analysis were: the mean change from baseline (33.3 %), the linear mixed model for repeated measures (22.2 %) and time to HRQoL score deterioration (18.5 %). For each targeted dimension, the results for each group, the estimated effect size and its precision were clearly reported in 4 studies (14.8 %), not clearly reported in 11 studies (40.7 %) and not reported at all in 12 studies (44.4 %).
Conclusions: This review demonstrated the weakness and the heterogeneity of the measurement, analysis, and reporting of HRQoL in phase III advanced NSCLC trials. Precise and uniform recommendations are needed to compare HRQoL results across publications and to provide understandable messages for patients and clinicians.

Keywords: Health-related quality of life, Lung cancer, Methodology
therapy approvals by the American Society of Clinical Oncology and the FDA [1, 4] HRQoL reflects the patient-perceived evaluation of one’s health, including physical, emotional, and social dimensions as well as symptoms due to disease or treatment. Several publications have underlined some key issues regarding the heterogeneity of HRQoL reporting in randomized clinical trials (RCTs) in oncology [5, 6]. Moreover, the statistical longitudinal analysis of HRQoL remains unstandardized which compromises the comparison of results between trials [7]. To improve the reporting of HRQoL in oncology randomized clinical trials, an extension to the CONSORT statement regarding HRQoL reporting was published.

Nevertheless, these guidelines do not detail the methodology of statistical analysis of HRQoL. Claassens et al. reported that some aspects of HRQoL reporting (missing HRQoL data, a priori hypotheses of HRQoL, rationale for instruments used) remain underrepresented in non-small-cell lung cancer (NSCLC) RCTs [6].

The aim of this review was to evaluate the three major steps of HRQoL analysis: measurement, statistical analysis, results presentation in phase III clinical trials of first-line chemotherapy in advanced NSCLC with a special focus on the statistical analysis.

**Methods**

**Search strategy and Selection for studies**

Eligible trials were randomized phase III trials of first-line chemotherapy in advanced NSCLC. Literature searches in PubMed database (January 2008 to December 2014) were performed. Trials published from 2008 were included to assess HRQoL analysis in recent trials. For PubMed database research, the following strategies were used: (lung neoplasm[MeSH Terms]) AND (advanced[Text Word] OR metastatic[Text Word]) + filters Clinical Trial, Phase III. In case of companion papers (i.e. HRQoL analyses reported in a separate paper; not in the princeps one), only the information and methodology declared in the HRQoL paper were reported.

**Data extraction**

Two authors (F. F., A.A) independently extracted information using predefined data abstraction forms. All data were checked for internal consistency, and disagreements were resolved by discussion among the investigators. The following details were extracted: general items (number of patients, year of publication, study period, number of centers, nationality of the first author, academic, mixed or industrial trial), name of the primary endpoint, items related to HRQoL measurement and reporting (rational for HRQoL assessment, methods of data collection, HRQoL questionnaire, evidence of HRQoL questionnaire validity, method/algorithm for scoring the questionnaire, planned schedule of questionnaires administration, results from each targeted dimensions for multidimensional questionnaires, method for results presentation, discussion of limitations and implications for generalizability and clinical practice.

We assessed statistical HRQoL analysis according to 13 key parameters: statement of the targeted dimensions, statement of the HRQoL hypothesis, procedure to control the type I error rate, statement of the minimal clinically important difference (MCID), data set for HRQoL analyses, description of the number of HRQoL data available at baseline and at subsequent time points, statement of HRQoL scores at baseline for each group and each dimension, profile of missing data at baseline, statement of statistical approaches for dealing with missing data, statistical approach for HRQoL analysis, MCID taken into account in the statistical analysis method and/or in the interpretation of the results, statement of the multivariate analysis. Each key point was coded as “yes” (2 points), “unclear” (1 point) or “no” (0 point). A score on a 0–26 scale was then created with a high score represent a high methodological level for statistical analysis.

**Data analyses**

We conducted a descriptive analysis of selected publications, HRQoL measurement, reporting and of the statistical analysis of HRQoL with each key point.

Quantitative variables were described with median and range. Qualitative variables were described with absolute frequencies (number) and relative frequencies (proportion).

Analyses were conducted with the use of SAS software, version 9.3 (SAS Institute).

**Results**

**HRQoL measurement**

A total of 55 phase III advanced NSCLC trials published between 2008 and 2014 were identified (Fig. 1). Among these studies, 27 trials were identified with HRQoL endpoint (49 %) (Fig. 1) including 2 studies with HRQoL as primary endpoint. Of the 27 studies, the background and rationale for HRQoL used was provided in 6 trials (22.2 %). For 5 trials (18.5 %), additional HRQoL publications were released in a separate HRQoL dedicated paper. Five trials (18.5 %) provided no result of HRQoL.

The EORTC Quality of Life Questionnaire C30 (QLQ-C30) was the most frequently used instrument. It was used in 13 (48 %) of the studies (Table 1). The lung cancer-specific module EORTC QLQ-LC13 was added to the QLQ-C30 in 12 studies (37 %). Among these 12 studies, two studies added the EuroQol EQ-5D generic questionnaire to the QLQ-C30 and QLQ-LC13. The Functional Assessment of Cancer Therapy (FACT) questionnaires were used in 12 studies (44.4 %): one study (3.7 %) used the FACT-General (FACT-G), 7 studies...
(25.9 %) used the FACT-L questionnaire specific for lung cancer patients and 4 studies (14.8 %) used the FACT-LCS which is a subset of the FACT-L with 7 items (Table 1). The Lung Cancer Symptom Scale questionnaire was used in 1 study (3.7 %). One study did not specify the HRQoL questionnaire used. The reference of the HRQoL instrument validation was provided in 13 studies (48 %). Among the 4 studies using the FACT questionnaires in other than English version, none of them reported the transcultural validation. Six studies (22.2 %) defined the procedure of questionnaire completion (i.e. paper and pencil, electronic completion, at home or at the clinic). The planned schedule of HRQoL assessment was reported in 23 trials (85.2 %).

**Statistical analysis of HRQoL**

The Table 2 summarized the quality of statistical analysis of HRQoL.

The mean score based on the 13 key parameters of the 27 trials was 6.3 (standard deviation = 6.1, range = 0-20). The targeted dimensions of HRQoL were pre-specified in 13 studies (48.1 %) in the method section: 6 of them used EORTC questionnaires and 7 used FACT questionnaires. Among the 6 studies which used EORTC questionnaires, 3 dimensions were targeted in mean and targeted dimensions were dyspnea (66.6 %), global health status (66.6 %), pain (50.0 %), fatigue (50.0 %), cough (33.3 %) and nausea/vomiting (33.3 %) (Table 1). Among the 7 studies which used FACT questionnaires, 2 dimensions were targeted in mean and most frequent targeted dimensions were the lung cancer subscale (57.2 %), the trial outcome index (57.2 %) and the FACT-L global score (28.6 %) (Table 1).

Nine studies (33.3 %) defined the MCID. Among these studies: 5 used the EORTC questionnaires and all of them used a 10-point decrease in the HRQoL scores as the MCID (Table 1), 4 used the FACT questionnaires and all of them used 6 points decrease for the FACT-L global score and trial outcome index, and 2 points decrease for the lung cancer subscale as the MCID.

The MCID was taken into account in the statistical analysis and/or in the interpretation of the results in 7 studies (25.9 %) (Table 1).

Only three studies mentioned the population data set for HRQoL analysis: 2 in modified intention-to-treat, 1 in intention-to-treat. Definition for the mITT population were 1) “all randomly assigned patients with data were included” [8] and 2) “patients with a baseline and at least one post-baseline HRQoL assessment were included” [9].

The number of HRQoL data at baseline and at subsequent time points, the HRQoL scores at baseline for each group and each dimension, the profile of missing data at baseline, the statistical approaches for dealing with missing data were adequately reported in 7 (25.9 %), 6 (22.2 %), 1 (3.7 %) and 5 (18.5 %) studies, respectively (Table 2). The statistical methods for dealing with missing data were different (Table 1). No study provided the reasons why data were missing.

Fourteen studies (51.9 %) described the statistical approach to analyze HRQoL data in the method section (Table 2). Seven studies used two or more statistical approaches. The different statistical methods/analyses were: the mean change from baseline (33.3 %), the linear mixed model for repeated measures (LMM) (22.2 %), time to HRQoL score deterioration (TTD) (18.5 %), AUC (7.4 %), mixed-effects growth-curve model (7.4 %), distribution of patients whose symptom had improved, remained stable or worsened (3.4 %), Fisher test for equal proportion of patients achieving at least two points increase (3.4 %), group comparisons of scale at each time (3.4 %), rates of symptom palliation (3.4 %), percentage of patients with at least two points improvement at the beginning of the cycle two (3.4 %) (Table 1). No study specified which were the primary statistical analysis and the sensitive analysis.

Among the six studies which used a LMM to analyze the longitudinal HRQoL data, none of them declared the
| First authors | HRQoL questionnaire | Timing of assessment | Targeted dimensions | MCID | Statistical approach for dealing with missing data | Statistical approach for HRQoL analysis |
|---------------|---------------------|---------------------|---------------------|------|-------------------------------------------------|-------------------------------------|
| Wu [19]       | QLQ-C30; QLQ-LC13   | Randomization and every 3 weeks until disease progression or new cancer treatment | Cough, dyspnoea, pain | 10 points | Distribution of patients whose symptom had improved, remained stable, or worsened; the time to deterioration of symptoms; mixed-effects growth curve model |
| Laurie [20]   | QLQ-C30; QLQ-LC13 and two additional questions (hand-foot syndrome and headache) | At baseline and every cycle | | | |
| Yang [7]      | QLQ-C30; QLQ-LC13   | Random assignment and every 21 days until disease progression | Cough, dyspnoea, pain | 10 | Joint analysis | Time to deterioration; mixed-effects growth curve model |
| Wu [19]       | FACT-L              | Not available        | FACT-L total score and TOI | | Time to deterioration |
| Yoshioka [21] | FACT-L; FACT/GOGNTX| At the time of enrollment and at 6 and 9 weeks after the initiation of treatment | | | Linear mixed model for repeated measures |
| Lee [22]      | QLQ-C30, QLQ-LC14, EUROQOL | Baseline, monthly during the first year, then 18 and 24 months after randomization | | | Linear mixed model for repeated measures |
| Gridelli [23] | QLQ-C30, QLQ-LC13   | Before each cycle, 3 weeks after the last cycle, and then every 8 weeks until 57 weeks | Global health status, health, nausea/vomiting, dyspnoea, fatigue | 10 | Mean change from baseline |
| Flotten [24]  | QLQ-C30, QLQ-LC13   | Baseline and on day 1 of each cycle | Peripheral neuropathy, pain, hearing, edema | | Mean change from baseline |
| Socinsky [25] | FACT-G, FACTTAXANE | Start of chemotherapy and weeks 6,12,16,24,30 | | | Mean change from baseline |
| Groen [26]    | QLQ-C30, QLQ-LC13   | Baseline and every 6 weeks | | | Mean change from baseline |
| Chen [9]      | FACT-L              | | | 6 for FACT-L total score and TOI; 2 points for LCS LCS | Mean change from baseline |
| Lara [27]     | QLQ-C30             | On day 1 of each odd cycle and at the end of the treatment visit | | | Mean change from baseline |
| Koch [12]     | QLQ-C30, QLQ-LC13   | Baseline, weeks 3,6,9,12,20,28 | Dyspnoea, fatigue, pain, pain medication, global health status | | Group comparisons of scale at each time; mean change from baseline; AUC; rates of symptom palliation |
| Biesma [28]   | QLQ-C30, QLQ-LC13   | Before, during (day 1 and day 8 of each cycle) and after each cycle (weeks 12,15,18) | Global health status | 10 | Mean change from baseline and week 18; linear mixed model for repeated measures |
| Study | Measure | Time Points | Methods | Analysis | HRQoL 
|-------|---------|-------------|---------|----------|---------------------------------------|
| Weissman [29] | FACT-L | After each cycle, TOI | | Mean change from baseline and after 6 cycles | |
| Okamoto [30] | FACT-L, FACT/GOGNTX | Time of enrollment and at 6 and 9 weeks after initiation of treatment | | Linear mixed model for repeated measures | |
| Thongprasert [31] | FACT-L | Baseline, weeks 1 AND 3, 3-weekly until week 18, 6 weekly until progression and at discontinuation | FACT-L Score, TOI, LCS 6 for FACT-L total score and TOI; 2 points for LCS | Mean change from baseline; Time to worsening; Time to improvement | |
| Lynch [32] | FACT-L | Baseline, before each treatment cycle and at the end of the therapy | | Mean change from baseline; Time to symptomatic disease progression | |
| Takeda [33] | FACT-L | The time of enrollment and at 12 weeks, 18 weeks after initiation of treatment | LCS | Linear mixed-effects model in which the missing data depend on the observed score | |
| Lee [34] | QLQ-C30, QLQ-LC14 | Random, During each cycle, at the end of the chemotherapy, every 6 months until 24 months | | Linear mixed model for repeated measures | |
| Treat [35] | FACT-L | Not available | LCS | Linear mixed model for repeated measures | |
| Tan [36] | Lung cancer symptom scale | Baseline, at the end of each cycle, just before the next cycle, at the end of the study | | | |
| Pirker [37] | QLQ-C30, QLQ-LC13, EuroQol EQ-5D | Not available | | | |
| Gronberg [38] | QLQ-C30, QLQ-LC13 | Weeks 0,3,6,9,12,20,28,36,44,52 | Global health status health, nausea/vomiting, dyspnoea, fatigue | Last value carried forward for missing value that followed, even after death | Area under the curve |
| O’Brien [39] | FACT-L | Baseline, before each cycle and at the end of the treatment | LCS | Missing scores at week 3 were classified as having less than a 2-point increase in the primary analysis data but classified as missing and excluded from the supplemental analysis | Fisher test for equal proportion of patients achieving at least two points increase |
| Langer [40] | FACT-L | Baseline and within 3 days of each treatment | LCS | Percentage of patients with at least two points improvement at the beginning of cycle 2 | |
| Gebbia [41] | QLQ-C30; QLQ-LC13 | Baseline and every cycle | | | |
effects introduced in the model (random or fixed effects and interactions).

One study presented a multivariate analysis (Table 2).

**HRQoL results presentation**

For each targeted dimension, the results for each group, the estimated effect size and its precision were adequately reported in four studies (14.8 %), not clearly reported in 11 studies (40.7 %) and not reported at all in 12 studies (44.4 %). A discussion specific limitations and implications for clinical practice was provided in 10 articles (37 %) (Table 1).

The results were presented in the text, figures or tables in 24 (88.9 %), 12 (44.4 %) and 8 (29.6 %) articles, respectively (Table 1).

**Discussion**

In this review, we showed that HRQoL was declared as an endpoint in only 49 % of the phase III clinical trials in advanced NSCLC published between 2008 and 2014. Moreover, we clearly demonstrated the heterogeneity and the weakness of the methodology of HRQoL measurement, statistical analysis and reporting. First, two questionnaires are the most widely used: the QLQ-C30 plus LC13 module (48 %) and the FACT-L (44 %). As an example, the OPTIMAL [8, 9] and the Lux-Lung 3 [10] trials compared the efficacy and tolerability of two tyrosine kinase inhibitor (erlotinib and afatinib, respectively) versus chemotherapy in first-line treatment of patients with advanced EGFR mutation-positive NSCLC. HRQoL was assessed by the FACT-L questionnaire in OPTIMAL trial [9] while EORTC QLQ-C30 and LC13 module were used in LUX-Lung 3 trial [7]. These two clinical trials could hardly be compared since EORTC and FACT questionnaires for lung cancer do not contain the same dimensions in regard to impact of lung cancer on HRQoL. Moreover, two studies used the EuroQoL EQ-5D generic questionnaire which comprises only five short questions and is suitable since it limits patient burden and in that way also encourages response rate. Nevertheless this questionnaire has not been tailored to the special requirements of patients with cancer. At this time, the foremost challenge would be to promote, through cancer site and treatment modalities, guidelines for selecting the best questionnaires allowing for direct comparison of results across trials. Moreover, it is also still necessary to develop some new tools to evaluate HRQoL. Already validated questionnaires may not be adapted to new targeted biotherapy agent which can induce some long-term moderate toxicities.

Then, the number of HRQoL measures and intervals between two consecutive measures vary from one study to another. HRQoL is often captured until tumor progression, nevertheless, in advanced NSCLC, we could wonder if it would be more appropriate to measure HRQoL until death. Recommendations on the schedule of HRQoL assessment should be provided. At least three HRQoL assessment are recommended: at baseline, during treatment and at the end of the study (http://groups.eortc.be/qol/eortc-qlq-c30). However, a more intensive HRQoL assessment is preferable to better capture the longitudinal trajectory of HRQoL level and to capture any relevant changes. In this review, most of studies evaluate HRQoL at baseline and then every treatment cycle which allow a good appreciation of the impact of treatment of HRQoL over time, but it depends on the number of cycles received by the patient. Moreover attention should be paid to the timing of diagnostic procedures which could influenced HRQoL results, especially with lifethreatening cancers. Patients are likely to be

### Table 2

|                              | Yes, n (%) | Not clear, n (%) | No, n (%) |
|------------------------------|------------|------------------|-----------|
| Targeted dimensions          | 13 (48.1)  | 0                | 14 (51.9) |
| HRQoL hypothesis             | 2 (7.4)    | 0                | 25 (92.6) |
| Procedure to control the type I error | 1 (3.7)    | 1 (3.7)          | 25 (92.6) |
| Minimal clinically important difference | 9 (33.3)   | 1 (3.7)          | 17 (63)   |
| Study population             | 3 (11.1)   | 3 (11.1)         | 21 (77.8) |
| Number of HRQoL data at subsequent time points | 7 (25.9)   | 6 (22.2)         | 14 (51.9) |
| HRQoL scores at baseline for each group and each dimension | 6 (22.2)   | 2 (7.4)          | 19 (70.4) |
| Profile of missing data at baseline | 1 (3.7)    | 2 (7.4)          | 24 (88.9) |
| Statistical approaches for dealing with missing data | 5 (18.5)   | 0                | 22 (81.5) |
| Statistical approach for HRQoL analysis | 14 (51.9)  | 1 (3.7)          | 12 (44.4) |
| MCID taken into account in the statistical analysis | 7 (25.9)   | 2 (7.4)          | 18 (66.7) |
| Multivariate analysis        | 1 (3.7)    | 0                | 26 (96.4) |
experiencing stress in anticipation of the yet unknown results. After the procedure, the patients will either be experiencing great relief or anxiety depending on the results. This point should be taken into account in HRQoL assessment design and be carefully documented in the protocol and emphasized during training.

The a priori selection of the targeted dimensions was heterogeneous between the trials and was pre-specified only 13 times (48.1 %) in the method section and most of them are symptomatic scales. We know that there is general agreement concerning the multidimensional concept of HRQoL taking into account levels of physical, mental, social, and patient satisfaction with treatment. Therefore, the choice of only symptomatic HRQoL dimensions reaches the problem of the holistic sense of HRQoL. Moreover, the choice of the targeted dimensions of HRQoL must be discussed between clinicians and methodologists and clearly described in the protocol.

In confirmatory clinical trials with multiple endpoints, the use of multiple test procedures is mandatory and CONSORT Statement recommends a multiplicity adjustment in case of multiple testing [11]. However, only one study clearly stated the procedure to control the type I error [12].

Prior to longitudinal HRQoL data analysis, the MCID should be a priori determined [13]. In our review, only nine studies (33.3 %) clearly specified it. The MCID represents the smallest changes/differences in HRQoL score, which is perceived as clinically important. For the EORTC questionnaires, a 5-point to a 10-point difference in scores could be considered as the MCID [14]. In patients with NSCLC, Maringwa et al. [15] tried to determine the smallest changes in HRQoL scores in a subset of the EORTC QLQ-C30 scales, which could be considered as clinically meaningful. They concluded that the estimates of 5 to 10 units of the QLQ-C30 scales may be used as guidance for clinicians and researchers to classify patients as improved or deteriorated. In our review, the 5 studies which used the QLQ-C30 and stated the MCID, all used a 10-point decrease in the HRQoL scores as the MCID. A sensitivity analysis, with a MCID of 5 points could have been proposed to assess the robustness of the results.

Missing data, considered as missing not at random, can bias the longitudinal analysis if it is not adequately taken into account [16]. Patients may drop out before the planned end of the study, resulting in the absence of any available HRQoL data after the patient’s drop out (i.e. attrition). Moreover, drop out occurs generally due to a deterioration of patient health status or death. Patients may also be too tired to fill the questionnaire entirely at a specific measurement time. This induces the potential risk to select subpopulation of patients with better HRQoL levels and with available HRQoL data. Not adjusting for missing data can limit the robustness of the results and the confidence in the HRQoL conclusions. Therefore, the profile of missing data at baseline and the number of HRQoL at subsequent time points for each group must be specified. In our review, these two information were reported in only 1 (3.7 %) and 7 (25.9 %) trials, respectively. Furthermore, only 5 studies (18.5 %) described the statistical approaches for dealing with missing data and the 5 methods were different. Thus, the reporting of missing data and the statistical approaches of analysis of missing data need to be standardized.

There are a number of possible ways of analyzing longitudinal HRQoL data. Currently, the two main robust methods are: the LMM and the TTD [6, 17]. In our review, the most widely used is the mean change from baseline (33.3 %). This method summarizes the longitudinal data into a summary statistic before performing a between-arms comparison. This method is rather simple but may overlook important changes in HRQoL along time and should not be applied. This method is not a model of longitudinal analysis. The LMM method was used in 6 studies (22.2 %). In all these studies the fixed effects, the random effects and the correlation matrix between HRQoL measures introduced in the model were not specified. Thus, results are very difficult to interpret. The LMM can estimate a time effect, an arm effect and an interaction between treatment arm and time (reflecting a different evolution of the two treatment arms over time). The LMM contains both fixed effects (reflecting average trends) such as treatment and random effects (individual trends). This model accounts for the association (i.e. correlation) of measures made on the same patient at different times.

Finally, the LMM model generally require a normally distribution of the score studied. All studies using this method did not mention this hypothesis and a priori did not check it. For EORTC questionnaires, scores generally do not respect a normal distribution due to the low number of items per dimension. The TTD approach was used in 5 studies (18.5 %). Currently the definition of the TTD is not standardized; therefore the studies must clearly define it. The definition of the TTD must include: reference score, the event of interest, the censoring process, including death or not [6]. In our review, only one study defined the TTD: “Time to deterioration in patient-reported outcomes was measured in months from random assignment to the first instance of symptom worsening (10 points from baseline). Patients without worsening, including those with disease progression, were censored at the last available patient-reported outcome assessment; those lacking post-baseline assessments were censored at random assignment. Patients who died without documented worsening were considered to have
deteriorated at the time of death” [7]. Other statistical methods were used: “distribution of patients whose symptom had improved, remained stable or worsened”, “Fisher test for equal proportion of patients achieving at least two points increase”, “group comparisons of scale at each time”, “rates of symptom palliation”, “percentage of patients with at least two points improvement at the beginning of the cycle two”. These methods can guide on the choice of the most appropriate analytical method to use to analyze longitudinal HRQoL data (e.g., the LMM or the TTD) approach. However, these analyses alone cannot be sufficient to capture all information present in the longitudinal HRQoL assessment and must be completed by a longitudinal statistical approach taking into account the correlation between HRQoL measures.

Finally, it should be acknowledged that journal space is often limited, and authors may not have been able to report all the methodology. Therefore, HRQoL may systematically be reported in separate HRQoL dedicated manuscripts.

Conclusions
Our review demonstrated the poor quality and the heterogeneity of the measurement, analysis, and reporting of HRQoL in phase III advanced NSCLC trials. The heterogeneity between trials limits their cross comparison and the feasibility of meta-analysis.

The HRQoL CONSORT statement regarding HRQoL reporting was published in 2013 [18] and it is true that we reviewed studies published before 2013. The use of the HRQoL CONSORT extensions should be encouraged. Nevertheless, these guidelines do not detail the methodology of statistical analysis of HRQoL. Incomplete or inaccurate statistical analysis of HRQoL can affect the reliability of these outcomes. Therefore, development of guidelines for longitudinal HRQoL analysis of clinical trials is important to facilitate interpretation of HRQoL findings.

Abbreviations
HRQoL: Health-related quality of life; NSCLC: Non-small cell lung cancer; FDA: Food and Drug Administration; OS: Overall survival; RT: Randomized clinical trial; MCID: Minimal clinically important difference; EORTC QLQ-C30: European organization for research and treatment of cancer quality of life questionnaire C30; FACT: Functional Assessment of Cancer Therapy; LMM: Linear mixed model for repeated measures; TTD: Time to health-related quality of life score deterioration.

Competing interests
The authors declare that they have no competing interests.

Authors’ contribution
Conception and design: FF, AA, VW, FB. Acquisition of data: FF, AA, Analysis and interpretation of data: FF, AA, VW, FB. Involved in drafting the manuscript or revising it critically for important intellectual content: FF, AA, VW, FB. Agree to be accountable for all aspects of the work in ensuring that questions related to the Accuracy or integrity of any part of the work are appropriately investigated and resolved: FF, AA, VW, FB. All authors have read and approved the manuscript.

Acknowledgements
No acknowledgement.

Author details
1Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, France. 2EA 3181. University of Franche-Comté, Besançon, France. 3The French National Platform Quality of Life and Cancer, Besançon, France. 4Department of Medical Oncology, University Hospital of Besançon, Besançon, France. 5CHEST disease Department, University Hospital of Besançon, Besançon, France. 6EORTC QOL Group, Brussels, Belgium.

Received: 1 July 2015 Accepted: 9 February 2016
Published online: 18 February 2016

References
1. Banz J, Gnecco C, Justice R. Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr. 1996(20):7-9. http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071590.pdf
2. Fiteni F, Westeel V, Pivot X, Borg C, Vernerey D, Bonnetaire F. Endpoints in cancer clinical trials. J Visc Surg. 2014;151(1):17–22.
3. Mathoulin-Pelissier S, Gouguou-Bourjade S, Bonnetaire F, Kamar A. Survival end point reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(22):3721–6.
4. Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep. 1985;69(10):1155–9.
5. Claassen L, van Meerbeeck J, Coens C, Quinten C, Ghislain I, Sloan EK, et al. Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(15):2104–20.
6. Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Basculu-Mollov C, Auquier P, et al. Time to healthrelated quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization? Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2015;24(1):15–18.
7. Yang J-C-H, Hirsh V, Schulmer Y, Yamamoto N, O’Byrne KJ, Mok TS, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib plus cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(27):3342–50.
8. Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.
9. Chen G, Feng J, Zhou C, Wu Y-L, Liu X-Q, Wang C, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol Off J Eur Soc Med Oncol. 2013;24(6):1615–22.
10. Sequist LV, Yang J-C-H, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase II study of afatinib or cisplatin/pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(27):3327–34.
11. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg Lond Engl. 2012;10(1):28–55.
12. Koch A, Bergman B, Holmberg E, Sederholm C, Ek L, Kosieradzki J, et al. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer Off J Eur. 2011;47(10):1546–55.
13. Jasschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407–15.
14. Ozoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(1):139–44.
15. Malinga JT, Quinten C, King M, Ringash J, Osoba D, Coens C, et al. Minimal important differences for interpreting health-related quality of life
scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Support Care Cancer Off J Multinat Assoc Support Care Cancer. 2011;19(11):1753–60.

16. Bernhard J, Cella DF, Coates AS, Fallowfield L, Ganz PA, Moinpour CM, et al. Missing quality of life data in cancer clinical trials: serious problems and challenges. Stat Med. 1998;17(5-7):517–32.

17. Fiteni F, Anota A, Westeel V, Bonnetain F. [Health-related quality of life in phase III cancer clinical trials: From questionnaire administration to statistical analysis]. Bull Cancer. (Paris). 2015;102(4):360–6.

18. Calvert M, Bazely J, Altman DG, Revicki DA, Moher D, Brundage MD, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA J Am Med Assoc. 2013;309(8):914–22.

19. Wu YJ, Lee JS, Thongprasert S, Yu C-J, Zhang L, Ladrera G, et al. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(1):1161–70.

20. Gindelli C, Ciardiello F, Gallo C, Feld R, Butts C, Geppetti P, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2012;13(11):1252–60.

21. Flöttén O, Grønberg BH, Skåstad P, Brunsvig PF, Hjelde HH, Grønberg BH, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WITO0203). J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(5):511–7.

22. Lee SM, Rudd R, Woll PJ, Ottervanger C, Aalberg J, Miki M, et al. Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(13):5248–54.

23. Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, et al. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2012;13(11):1161–70.

24. Groen HJM, Sietsma H, Vincent A, Hochstenbach MMM, van Putten WJW, van den Berg A, et al. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with ceplucoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the TOMCH randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(24):3002–11.

25. Lara PN, Douillard J-Y, Nakaoka K, von Pawel J, McKeage MJ, Albert I, et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vandetanib (ASHA404) in advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(22):2965–71.

26. Lynch TJ, Patel T, Dreibruch L, McCleod M, Heim W, Hermann RC, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BM5099. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(6):511–7.

27. Takeda K, Hida T, Sato T, Ando M, Seto T, Satouchi M, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib in patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WITO0203). J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(5):511–7.

28. Lee SM, Rudd R, Woll PJ, Ottervanger C, Aalberg J, Miki M, et al. Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(13):5248–54.

29. Wei SJ, Lee JS, Thongprasert S, Yu C-J, Zhang L, Ladrera G, et al. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS phase III trial. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(5):1326–31.

30. Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, et al. Phase III randomized trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WITO0203). J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(5):511–7.

31. Fiteni F, Anota A, Westeel V, Bonnetain F. [Health-related quality of life in phase III cancer clinical trials: From questionnaire administration to statistical analysis]. Bull Cancer. (Paris). 2015;102(4):360–6.

32. Lynch TJ, Patet T, Dreibruch L, McCleod M, Heim W, Hermann RC, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BM5099. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(6):511–7.